M
Michael B. Sporn
Researcher at Dartmouth College
Publications - 561
Citations - 96644
Michael B. Sporn is an academic researcher from Dartmouth College. The author has contributed to research in topics: Transforming growth factor & Transforming growth factor beta. The author has an hindex of 157, co-authored 559 publications receiving 94605 citations. Previous affiliations of Michael B. Sporn include Cornell University & Reata Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Transforming Growth Factor Beta-1 in Acute Myocardial Infarction in Rats
Nancy L. Thompson,Fernando Bazoberry,Edith Speir,Ward Casscells,Victor J. Ferrans,Kathleen C. Flanders,Patljru Kondaiah,Andrew G. Geiser,Michael B. Sporn +8 more
TL;DR: A significant role for TGF-beta in the response of the heart to injury is indicated, as shown by the results of immunohistochemical staining and Northern blot analysis of mRNA.
Journal ArticleDOI
Transforming growth factor-beta. Major role in regulation of extracellular matrix.
TL;DR: The ability of TGF-β to improve and/or accelerate tissue repair has been studied extensively in a variety of animal models of both normal and impaired healing.
Journal ArticleDOI
Transforming growth factor-beta. Multiple actions and potential clinical applications.
TL;DR: TGF-β was identified originally in an assay that measured its ability to enhance the growth of fibroblasts in soft agar ("transformation"), its true importance is as a mediator of normal cellular physiology, in particular during normal formation of tissues and during tissue response to injury.
Journal ArticleDOI
The transforming growth factor-betas: past, present, and future.
TL;DR: The present volume on transforming growth factor-betas (TGF-0s) provides a summation of the current excitement in research on this family of peptides and briefly summarizes the present range of E F p studies.
Journal ArticleDOI
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole
Melinda S. Yates,Mi Kyoung Kwak,Patricia A. Egner,John D. Groopman,Sridevi Bodreddigari,Thomas R. Sutter,Karen J. Baumgartner,Bill D. Roebuck,Karen T. Liby,Mark M. Yore,Tadashi Honda,Gordon W. Gribble,Michael B. Sporn,Thomas W. Kensler +13 more
TL;DR: The unparalleled potency of CDDO-Im in vivo highlights the chemopreventive promise of targeting Nrf2 pathways with triterpenoids and dramatically block hepatic tumorigenesis.